The RSI Oscillator for BBLG moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 47 similar instances when the indicator left oversold territory. In 40 of the 47 cases the stock moved higher. This puts the odds of a move higher at 85%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for BBLG just turned positive on November 09, 2026. Looking at past instances where BBLG's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.
Following a +6.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBLG advanced for three days, in 145 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BBLG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBLG as a result. In 83 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBLG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BBLG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.234) is normal, around the industry mean (3.498). P/E Ratio (-1.191) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. BBLG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBLG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RXST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 45 cases where RXST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RXST's RSI Indicator exited the oversold zone, 35 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on RXST as a result. In 66 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for RXST just turned positive on November 09, 2026. Looking at past instances where RXST's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Following a +7.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXST advanced for three days, in 236 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 61 cases where RXST's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for RXST entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.717) is normal, around the industry mean (4.142). P/E Ratio (-3.982) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.749) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. RXST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BBLG | ||
|---|---|---|
OUTLOOK RATING 1..100 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 92 | |
P/E GROWTH RATING 1..100 | 7 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BBLG | RXST | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 81% |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| Advances ODDS (%) | 3 days ago 82% | 2 days ago 79% |
| Declines ODDS (%) | 9 days ago 90% | 9 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 88% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BBLG’s FA Score shows that 2 FA rating(s) are green while RXST’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BBLG’s TA Score shows that 5 TA indicator(s) are bullish while RXST’s TA Score has 5 bullish TA indicator(s).
BBLG (@Biotechnology) experienced а -3.48% price change this week, while RXST (@Medical/Nursing Services) price change was +6.75% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
BBLG is expected to report earnings on Mar 03, 2027.
RXST is expected to report earnings on Mar 03, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor tells us that BBLG and DYAI have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BBLG and DYAI's prices will move in lockstep.
| Ticker / NAME | Correlation To BBLG | 1D Price Change % | ||
|---|---|---|---|---|
| BBLG | 100% | -0.67% | ||
| DYAI - BBLG | 27% Poorly correlated | -3.84% | ||
| NTLA - BBLG | 26% Poorly correlated | -7.76% | ||
| RXST - BBLG | 25% Poorly correlated | +0.82% | ||
| PSNL - BBLG | 25% Poorly correlated | -0.44% | ||
| DNA - BBLG | 25% Poorly correlated | -2.91% | ||
More | ||||
A.I.dvisor indicates that over the last year, RXST has been loosely correlated with GMED. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if RXST jumps, then GMED could also see price increases.
| Ticker / NAME | Correlation To RXST | 1D Price Change % | ||
|---|---|---|---|---|
| RXST | 100% | +0.82% | ||
| GMED - RXST | 39% Loosely correlated | -1.49% | ||
| DCTH - RXST | 34% Loosely correlated | -0.84% | ||
| STE - RXST | 32% Poorly correlated | +0.07% | ||
| UFPT - RXST | 32% Poorly correlated | -1.51% | ||
| ESTA - RXST | 31% Poorly correlated | -1.88% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ENFR | 37.49 | 0.53 | +1.43% |
| Alerian Energy Infrastructure ETF (ENFR) | |||
| PXE | 39.00 | 0.33 | +0.85% |
| Invesco Energy Exploration & Production ETF (PXE) | |||
| BDGS | 36.50 | 0.02 | +0.06% |
| Bridges Capital Tactical ETF (BDGS) | |||
| PMAU | 26.97 | -0.04 | -0.14% |
| PGIM S&P 500 Max Buffer ETF - August (PMAU) | |||
| DFGP | 52.84 | -0.30 | -0.57% |
| Dimensional Global Core Plus Fixed Income ETF (DFGP) | |||